What is the primary reason for the increased net loss in Q3 2003?

The primary reason for the increased net loss of $86.4 million in Q3 2003, compared to $33.5 million in Q3 2002, was a significant restructuring and other expense of $42.4 million. This charge is primarily related to anticipated lease restructuring costs for a facility that Vertex decided not to occupy, reflecting unfavorable real estate market conditions in Cambridge, Massachusetts.

What is the significance of the Lexiva (fosamprenavir calcium) approval?

The U.S. FDA granted marketing clearance for Lexiva in late October 2003, and GlaxoSmithKline launched it in early November 2003. As a co-promoted HIV protease inhibitor with Agenerase, Lexiva's launch is expected to contribute to increased royalty revenues for Vertex in future periods.

How has the sale of the Discovery Tools and Services business impacted revenues?

The sale of certain assets from the Discovery Tools and Services business to Invitrogen Corporation in March 2003 significantly reduced revenues in this segment. For Q3 2003, total revenues for this segment were $2.5 million, down from $12.9 million in Q3 2002, primarily due to the divestiture of reagent, probe, and assay capabilities. The remaining instrumentation assets continue to contribute to revenue.

What is Vertex's financial outlook, considering the ongoing losses?

Vertex expects to continue incurring losses for the foreseeable future due to significant investments in research and development for its drug candidates. However, the company projects full-year 2003 total revenues of approximately $80 million and anticipates its cash and marketable securities will exceed $550 million by the end of 2003, providing ample funding for operations and R&D initiatives.

VRTX 10-Q Quarterly Report Q3 FY2003 — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals Inc. reported a significant net loss of $86.4 million for the third quarter of 2003, a substantial increase from the $33.5 million loss in the same period last year. This widened loss was primarily driven by a large restructuring and other expense of $42.4 million, largely attributed to anticipated lease restructuring costs due to unfavorable real estate market conditions in Cambridge, Massachusetts. While total revenues declined year-over-year, driven by a decrease in the Discovery Tools and Services segment following an asset sale, the company saw a modest increase in its Pharmaceuticals segment, primarily from collaborative research and development. The company highlighted the FDA approval and subsequent launch of Lexiva (fosamprenavir calcium) in early November 2003, co-promoted with GlaxoSmithKline, which is expected to boost future royalty revenues. Despite ongoing losses and significant restructuring charges, Vertex maintained a strong cash and marketable securities position, exceeding $595 million at the end of the quarter, providing substantial runway for its R&D initiatives.

Key Highlights

1Significant increase in net loss to $86.4 million in Q3 2003, largely due to a $42.4 million restructuring and other expense related to lease obligations.
2FDA approval and U.S. launch of Lexiva (fosamprenavir calcium) in November 2003, expected to contribute to future royalty revenues.
3Total revenues decreased by 47% year-over-year to $18.4 million, primarily due to the sale of Discovery Tools and Services assets.
4Research and development expenses remained high, totaling $50.0 million for the quarter, with continued investment in drug candidates across infectious diseases, autoimmune/inflammatory diseases, and oncology.
5The company sold certain assets of its Discovery Tools and Services business to Invitrogen Corporation in March 2003, recording a $69.7 million gain.
6Vertex continues to focus on advancing its drug pipeline, with 13 drug candidates in pre-clinical or clinical development, including key Vertex-driven programs and partner-driven collaborations.
7Despite operating losses, the company maintained a strong liquidity position with over $595 million in cash and marketable securities as of September 30, 2003.

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2003

Summary

Key Highlights

Frequently Asked Questions